Abstract: An HLA-A2 restricted tumor antigen peptide originated fromr SART-1, derivatives thereof having characteristics functionally equivalent thereto; therapeutic, prophylactic or diagnostic agents for tumors which utilize the tumor antigen peptide or its derivative, a recombinant DNA, recombinant polypeptide or antibody related to said tumor antigen peptide, or use thereof; an antigen presenting cell presenting the said tumor antigen peptide or use thereof; cytotoxic T lymphocyte specific for said tumor antigen peptide or use thereof.

Abstract: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises the polynucleotide are provided.

Abstract: Tumor antigen peptide derivatives which comprise all or part of an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO: 3 through the alteration of one to several amino acid residues, which are capable of binding to HLA-A24 antigen and thus being recognized by cytotoxic T cells; the use of these tumor antigen peptide derivatives in treating, preventing and diagnosing tumors; and remedies or preventives for tumors containing these peptide derivatives as an active ingredient.

Abstract: A DNA consisting of the base sequence represented by SEQ ID NO: 1 or a DNA hybridizing with a DNA consisting of the base sequence represented by SEQ ID NO: 1 under stringent conditions and encoding a protein having activities as a tumor antigen; an expression plasmid containing the above DNA; a transformant transformed therewith; a tumor antigen protein produced as a result of expression of the above DNA; an antibody against the above protein; and the use thereof in the treatment, prevention or diagnosis of tumors.

Abstract: A tumor antigen peptide capable of inducing and/or activating HLA-A24-restricted and/or HLA-A2-restricted and tumor-specific cytotoxic T lymphocytes functions by providing a polynucleotide encoding the peptide and a complementary strand thereto, a recombinant vector containing the polynucleotide, a transformant containing the recombinant vector, a method for producing the peptide, an antibody against the peptide, a compound interacting with these entities and a method for screening for the compound, a pharmaceutical composition utilizing these entities, and a means for the diagnosis utilizing these entities.

Abstract: A method of gene diagnosis of diseases wherein TNF-&agr; promoters participate, such as juvenile rheumatoid arthritis, chronic rheumatism or diabetes, by determining in the nucleotides at the −857, −863 and/or −1031 positions in the 5′-flanking region of a TNF-&agr; gene.